Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor.

Abstract:

:Risk of relapse during the unrelated donor coordination period biases comparisons between allogeneic hematopoietic stem cell transplantation from an HLA 8 of 8 allele-matched unrelated donor (8/8 MUD) and that from a related donor with an HLA-1 antigen mismatch in the graft-versus-host (GVH) direction (RD/1AGMM-GVH). To reduce this bias, we performed a decision analysis focusing on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in first complete remission (CR1). The primary outcome measure was 5-year survival probability with or without quality-of-life (QOL) adjustment. A baseline analysis showed that the decision to perform MUD transplantation was superior to that to perform RD/1AGMM-GVH transplantation for patients with AML or ALL. However, in the ALL cohort, the direction of superiority was reversed when the interval between CR1 and 8/8 MUD transplantation was >5.5 months (without QOL adjustment) or >6 months (after QOL adjustment) or when overall survival of RD/1AGMM-GVH transplantation improved by 1.3% without QOL adjustment and 2.1% after QOL adjustment. In conclusion, 8/8 MUD should be prioritized in transplantation for AML and ALL in CR1. However, the MUD coordination period and improvements in RD/1AGMM-GVH transplantation might change the donor selection priority in transplantation for ALL in CR1.

journal_name

Blood Cancer J

journal_title

Blood cancer journal

authors

Kanda J,Fuji S,Kato S,Takami A,Tanaka J,Miyamura K,Ohashi K,Fukuda T,Ozawa Y,Kanamori H,Eto T,Kobayashi N,Iwato K,Morishima Y,Sakamaki H,Atsuta Y,Kanda Y,HLA Working Group.,Donor\/Source Working Group.,Adult AML Wor

doi

10.1038/bcj.2014.85

subject

Has Abstract

pub_date

2014-12-05 00:00:00

pages

e263

issn

2044-5385

pii

bcj201485

journal_volume

4

pub_type

临床试验,杂志文章,多中心研究
  • Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.

    abstract::We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal protein (M) and/or immunoglobulin (Ig) (M/Ig) within the first 6 months of diagnosis (only if M-protein ⩾3 g/dl) an...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2016.65

    authors: Ravi P,Kumar S,Larsen JT,Gonsalves W,Buadi F,Lacy MQ,Go R,Dispenzieri A,Kapoor P,Lust JA,Dingli D,Lin Y,Russell SJ,Leung N,Gertz MA,Kyle RA,Bergsagel PL,Rajkumar SV

    更新日期:2016-07-29 00:00:00

  • Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

    abstract::We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confirmed in 96 of 2732 t...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bcj.2016.114

    authors: Jones JR,Cairns DA,Gregory WM,Collett C,Pawlyn C,Sigsworth R,Striha A,Henderson R,Kaiser MF,Jenner M,Cook G,Russell NH,Williams C,Pratt G,Kishore B,Lindsay J,Drayson MT,Davies FE,Boyd KD,Owen RG,Jackson GH,Morga

    更新日期:2016-12-09 00:00:00

  • Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients.

    abstract::Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of co...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-020-0283-8

    authors: Medina A,Jiménez C,Sarasquete ME,González M,Chillón MC,Balanzategui A,Prieto-Conde I,García-Álvarez M,Puig N,González-Calle V,Alcoceba M,Cuenca I,Barrio S,Escalante F,Gutiérrez NC,Gironella M,Hernández MT,Sureda A,Ori

    更新日期:2020-02-06 00:00:00

  • CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

    abstract::Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. W...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-018-0097-0

    authors: Ayed AO,Chiappella A,Pederson L,Laplant BR,Congiu AG,Gaidano G,Spina M,Re A,Cavallo F,Musuraca G,Macon WR,Witzig T,Vitolo U,Nowakowski GS

    更新日期:2018-06-26 00:00:00

  • Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.

    abstract::Microarray analysis of the multiple myeloma (MM) miRNome has unraveled the differential expression of miRNAs in cytogenetic subgroups, their involvement in the tumor biology and their effectiveness in prognostic models. Herein, the small RNA transcriptional landscape in MM has been investigated exploiting the possibil...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-019-0184-x

    authors: Agnelli L,Bisognin A,Todoerti K,Manzoni M,Taiana E,Galletti S,Cutrona G,Gaffo E,Bortoluzzi S,Neri A

    更新日期:2019-02-19 00:00:00

  • Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.

    abstract::Circulating vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and selectins were prospectively measured in 145 newly-diagnosed patients with symptomatic myeloma (NDMM), 61 patients with asymptomatic/smoldering myeloma (SMM), 47 with monoclonal gammopathy of undetermined significanc...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2016.37

    authors: Terpos E,Migkou M,Christoulas D,Gavriatopoulou M,Eleutherakis-Papaiakovou E,Kanellias N,Iakovaki M,Panagiotidis I,Ziogas DC,Fotiou D,Kastritis E,Dimopoulos MA

    更新日期:2016-05-27 00:00:00

  • Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders.

    abstract::Waldenström's macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder (LPD) of post-germinal center nature. Despite the fact that the precise molecular pathway(s) leading to WM remain(s) to be elucidated, a hallmark of the disease is the absence of the immunoglobulin heavy chain class switch recombinati...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2012.35

    authors: Perrot A,Pionneau C,Azar N,Baillou C,Lemoine FM,Leblond V,Merle-Béral H,Béné MC,Herbrecht R,Bahram S,Vallat L

    更新日期:2012-09-07 00:00:00

  • Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.

    abstract::This corrects the article DOI: 10.1038/bcj.2015.86. ...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,已发布勘误

    doi:10.1038/bcj.2017.100

    authors: Saito H,Maruyama D,Maeshima AM,Makita S,Kitahara H,Miyamoto K,Fukuhara S,Munakata W,Suzuki T,Kobayashi Y,Taniguchi H,Tobinai K

    更新日期:2017-11-03 00:00:00

  • The blind men and the AML elephant: can we feel the progress?

    abstract::The pharmacological therapy of non-promyelocytic acute myeloid leukemia (AML) has remained unchanged for over 40 years with an anthracycline-cytarabine combination forming the backbone of induction treatments. Nevertheless, the survival of younger patients has increased due to improved management of the toxicity of th...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,评审

    doi:10.1038/bcj.2016.33

    authors: Tauro S

    更新日期:2016-05-13 00:00:00

  • Familial associations of lymphoma and myeloma with autoimmune diseases.

    abstract::Many B-cell neoplasms are associated with autoimmune diseases (AIDs) but most evidence is based on a personal rather than a family history of AIDs. Here we calculated risks for non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma (MM) when family members were diagnosed with any of 44 different AIDs, ...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2016.123

    authors: Hemminki K,Försti A,Sundquist K,Sundquist J,Li X

    更新日期:2017-01-06 00:00:00

  • Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting.

    abstract::Cancer cells have distinct metabolomic profile. Metabolic enzymes regulate key oncogenic signaling pathways and have an essential role on tumor progression. Here, serum metabolomic analysis was performed in 45 patients with T-cell lymphoma (TCL) and 50 healthy volunteers. The results showed that dysregulation of choli...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2015.10

    authors: Xiong J,Bian J,Wang L,Zhou JY,Wang Y,Zhao Y,Wu LL,Hu JJ,Li B,Chen SJ,Yan C,Zhao WL

    更新日期:2015-03-13 00:00:00

  • Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

    abstract::We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/s41408-019-0260-2

    authors: van Oers M,Smolej L,Petrini M,Offner F,Grosicki S,Levin MD,Davis J,Banerjee H,Stefanelli T,Hoever P,Geisler C

    更新日期:2019-12-04 00:00:00

  • A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

    abstract::Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cytogenetic studies are performed to assess prognosis but with limited impact on therapeutic decisions. Recently, several recurrently mutated genes have been described, but their clinical value remains to be defined. There...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2016.72

    authors: Bolli N,Li Y,Sathiaseelan V,Raine K,Jones D,Ganly P,Cocito F,Bignell G,Chapman MA,Sperling AS,Anderson KC,Avet-Loiseau H,Minvielle S,Campbell PJ,Munshi NC

    更新日期:2016-09-02 00:00:00

  • Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.

    abstract::Pediatric leukemia survival rates have improved dramatically over the past decades. However, current treatment protocols are still largely ineffective in cases of relapsed leukemia and are associated with a significant rate of chronic health conditions. Thus, there is a continued need for new therapeutic options. Here...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2012.46

    authors: Brandao LN,Winges A,Christoph S,Sather S,Migdall-Wilson J,Schlegel J,McGranahan A,Gao D,Liang X,Deryckere D,Graham DK

    更新日期:2013-01-25 00:00:00

  • Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.

    abstract::Cytogenetic abnormalities are found in most multiple myeloma (MM) patients. Although their prognostic value has been well studied, there are limited data on the association of primary cytogenetic abnormalities with disease characteristics and treatment response. This study was designed to evaluate these associations. ...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-020-00348-5

    authors: Abdallah N,Rajkumar SV,Greipp P,Kapoor P,Gertz MA,Dispenzieri A,Baughn LB,Lacy MQ,Hayman SR,Buadi FK,Dingli D,Go RS,Hwa YL,Fonder A,Hobbs M,Lin Y,Leung N,Kourelis T,Warsame R,Siddiqui M,Lust J,Kyle RA,Bergsage

    更新日期:2020-08-11 00:00:00

  • Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.

    abstract::Copy number alterations (CNAs) of 9p24.1 occur frequently in Hodgkin lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), primary central nervous system lymphoma, and primary testicular lymphoma, resulting in overexpression of PD-L1 and sensitivity to PD-1 blockade-based immunotherapy. While 9p24.1 CNA was als...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-019-0233-5

    authors: Wang Y,Wenzl K,Manske MK,Asmann YW,Sarangi V,Greipp PT,Krull JE,Hartert K,He R,Feldman AL,Maurer MJ,Slager SL,Nowakowski GS,Habermann TM,Witzig TE,Link BK,Ansell SM,Cerhan JR,Novak AJ

    更新日期:2019-08-30 00:00:00

  • MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias.

    abstract::CXCR4 is a negative prognostic marker in acute myeloid leukemias (AMLs). Therefore, it is necessary to develop novel ways to inhibit CXCR4 expression in leukemia. AMD3100 is an inhibitor of CXCR4 currently used to mobilize cancer cells. CXCR4 is a target of microRNA (miR)-146a that may represent a new tool to inhibit ...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2011.24

    authors: Spinello I,Quaranta MT,Riccioni R,Riti V,Pasquini L,Boe A,Pelosi E,Vitale A,Foà R,Testa U,Labbaye C

    更新日期:2011-06-01 00:00:00

  • High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

    abstract::In acute myeloid leukemia (AML), risk stratification based on cytogenetics and mutation profiling is essential but remains insufficient to select the optimal therapy. Accurate biomarkers are needed to improve prognostic assessment. We analyzed RNA sequencing and survival data of 430 AML patients and identified HMGA2 a...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-018-0103-6

    authors: Marquis M,Beaubois C,Lavallée VP,Abrahamowicz M,Danieli C,Lemieux S,Ahmad I,Wei A,Ting SB,Fleming S,Schwarer A,Grimwade D,Grey W,Hills RK,Vyas P,Russell N,Sauvageau G,Hébert J

    更新日期:2018-07-19 00:00:00

  • Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.

    abstract::We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide-dexamethasone (Rd) as initial therapy and had a time to progression of 72 months or longer. Of 240 patients, we identified 33 exceptional responders. Twenty-five patients ...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2015.91

    authors: Vu T,Gonsalves W,Kumar S,Dispenzieri A,Lacy MQ,Buadi F,Gertz MA,Rajkumar SV

    更新日期:2015-10-23 00:00:00

  • Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype.

    abstract::Monosomal karyotype (MK) defined by either ⩾2 autosomal monosomies or single monosomy with at least one additional structural chromosomal abnormality is associated with a dismal prognosis in patients with acute myeloid leukemia (AML). It was detected in 174 of 3041 AML patients in South Korean Registry. A total of 119...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2015.84

    authors: Jang JE,Min YH,Yoon J,Kim I,Lee JH,Jung CW,Shin HJ,Lee WS,Lee JH,Hong DS,Kim HJ,Kim HJ,Park S,Lee KH,Jang JH,Chung JS,Lee SM,Park J,Park SK,Ahn JS,Min WS,Cheong JW,Korean Society of Hematology AML\/MDS Working

    更新日期:2015-10-16 00:00:00

  • High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.

    abstract::Periostin is an extracellular matrix protein that is implicated in the biology of normal bone remodeling and in different cancer cell growth and metastasis. However, there is no information on the role of periostin in multiple myeloma (MM). Thus, we evaluated periostin in six myeloma cell lines in vitro; in the bone m...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2016.90

    authors: Terpos E,Christoulas D,Kastritis E,Bagratuni T,Gavriatopoulou M,Roussou M,Papatheodorou A,Eleutherakis-Papaiakovou E,Kanellias N,Liakou C,Panagiotidis I,Migkou M,Kokkoris P,Moulopoulos LA,Dimopoulos MA

    更新日期:2016-10-07 00:00:00

  • Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment.

    abstract::The aim of this study was to investigate the effects of a non-standard, intermittent imatinib treatment in elderly patients with Philadelphia-positive chronic myeloid leukaemia and to answer the question on which dose should be used once a stable optimal response has been achieved. Seventy-six patients aged ⩾65 years ...

    journal_title:Blood cancer journal

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bcj.2015.75

    authors: Russo D,Malagola M,Skert C,Cancelli V,Turri D,Pregno P,Bergamaschi M,Fogli M,Testoni N,De Vivo A,Castagnetti F,Pungolino E,Stagno F,Breccia M,Martino B,Intermesoli T,Cambrin GR,Nicolini G,Abruzzese E,Tiribelli M,B

    更新日期:2015-09-18 00:00:00

  • A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.

    abstract::Newly diagnosed AL amyloidosis patients were evaluated to develop a model for early assessment of treatment benefit at 6 months, integrating both hematologic (HR) and organ response (OR) assessment (testing cohort, Mayo: n = 473; validation cohort, Pavia: n = 575). Multiple OR were assessed as follows: All OR (AOR): r...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-020-0306-5

    authors: Sidana S,Milani P,Binder M,Basset M,Tandon N,Foli A,Dispenzieri A,Gertz MA,Hayman SR,Buadi FK,Lacy MQ,Kapoor P,Leung N,Rajkumar SV,Merlini G,Palladini G,Kumar SK

    更新日期:2020-04-14 00:00:00

  • High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

    abstract::Mutations in exon 9 of the calreticulin gene (CALR) frequently occur in patients with chronic myeloproliferative neoplasms (MPN). Patients exhibit spontaneous cellular immune responses to epitopes derived from the mutant CALR C-terminus, and CALR-mutant-specific T cells recognize autologous CALR-mutant malignant cells...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-018-0166-4

    authors: Holmström MO,Ahmad SM,Klausen U,Bendtsen SK,Martinenaite E,Riley CH,Svane IM,Kjær L,Skov V,Ellervik C,Pallisgaard N,Hasselbalch HC,Andersen MH

    更新日期:2019-01-17 00:00:00

  • Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

    abstract::Effect of alternative splicing (AS) on diffuse large B-cell lymphoma (DLBCL) pathogenesis and survival has not been systematically addressed. Here, we compared differentially expressed genes and exons in association with survival after chemoimmunotherapy, and between germinal center B-cell like (GCB) and activated B-c...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bcj.2017.71

    authors: Leivonen SK,Taskinen M,Cervera A,Karjalainen-Lindsberg ML,Delabie J,Holte H,Lehtonen R,Hautaniemi S,Leppä S

    更新日期:2017-08-25 00:00:00

  • Molecular pathways of early CD105-positive erythroid cells as compared with CD34-positive common precursor cells by flow cytometric cell-sorting and gene expression profiling.

    abstract::Special attention has recently been drawn to the molecular network of different genes that are responsible for the development of erythroid cells. The aim of the present study was to establish in detail the immunophenotype of early erythroid cells and to compare the gene expression profile of freshly isolated early er...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2012.45

    authors: Machherndl-Spandl S,Suessner S,Danzer M,Proell J,Gabriel C,Lauf J,Sylie R,Klein HU,Béné MC,Weltermann A,Bettelheim P

    更新日期:2013-01-11 00:00:00

  • Improved outcome for AML patients over the years 2000-2014.

    abstract::Few recent studies from registries have reported an improvement in overall survival of younger patients with acute myeloid leukemia (AML). However, reasons for this improvement are not defined. We analyzed the therapeutic course and outcome of 976 patients treated by intensive chemotherapy between 2000 and 2014. The n...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/s41408-017-0011-1

    authors: Bertoli S,Tavitian S,Huynh A,Borel C,Guenounou S,Luquet I,Delabesse E,Sarry A,Laurent G,Attal M,Huguet F,Bérard E,Récher C

    更新日期:2017-11-29 00:00:00

  • Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance.

    abstract::We previously reported that CagA can be translocated into B cells in Helicobacter pylori (HP) coculture media, and the translocation appears biologically significant as activation of the relevant cellular pathways was noticed. In this study, we further explore if CagA can be detected in malignant B cells of HP-positiv...

    journal_title:Blood cancer journal

    pub_type: 杂志文章

    doi:10.1038/bcj.2013.22

    authors: Kuo SH,Chen LT,Lin CW,Wu MS,Hsu PN,Tsai HJ,Chu CY,Tzeng YS,Wang HP,Yeh KH,Cheng AL

    更新日期:2013-07-12 00:00:00

  • Interpretation of cytogenetic results in multiple myeloma for clinical practice.

    abstract::The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a challenging task. MM is characterized by several cytogenetic abnormalities that occur at various time points in the disease course. The interpretation of cytogenetic results in MM is complicated by the number and complexity of the abno...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,评审

    doi:10.1038/bcj.2015.92

    authors: Rajan AM,Rajkumar SV

    更新日期:2015-10-30 00:00:00

  • Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.

    abstract::This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). Patients progressing on or after standard therapy received intravenous isatuximab (weekly [QW] or every 2 weeks [Q2W]). The primary objective was t...

    journal_title:Blood cancer journal

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41408-019-0198-4

    authors: Martin T,Strickland S,Glenn M,Charpentier E,Guillemin H,Hsu K,Mikhael J

    更新日期:2019-03-29 00:00:00